Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: Resufts of one-year follow-up

Journal of Endocrinological Investigation

Volumn 32, Issue 2, 2009, Pages 134-138

  Regalbuto, C ^a   Marturano, I ^a   Condorelli, A ^a   Latina, A ^a   Pezzino, V ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

Author keywords

Graves disease; Guidelines; Hypothyroidism; Toxic adenoma

Indexed keywords

IODINE 131; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; ECHOGRAPHY; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RECURRENT DISEASE; THYROID ADENOMA; THYROID SCINTISCANNING; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 67649399553     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345702     Document Type: Article

References (34)

1. Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves' disease. J Gun Invest 1942, 21: 624 (abstract).
2. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: The early history. Thyroid 1997, 7: 163-76.
3. Read CH Jr, Tansey M Jr. Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004, 89: 4229-33.
4. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998, 280: 347-55.
5. Gómez-Arnaiz N, Andia E, Gumà A, Abós R, Soler J, Gómez JM. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Horm Metab Res 2003, 35: 492-7.
6. Erdogan MF, Küçuk NO, Anil C, et al. Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas. Nucl Med Commun 2004, 25: 1083-7.
7. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol 2004, 61: 641-8.
8. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003, 88: 978-83.
9. Franklyn JA, Daykin J, Droic Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991, 34: 71-6.
10. Nordyke RA, Gilbert Fl Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J NucI Med 1991, 32: 411-6.
11. Watson AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG. Outcome following standardized 185 MBq dose 1311 therapy for Graves'disease. Clin Endocrinol (Oxf) 1988, 28: 487-96.
12. Jarløv AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol (Oxf) 1995, 43: 325-9.
13. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot U. Long-term follow-up study of compensated low-dose 1311 therapy for Graves' disease. N Engl J Med 1984, 311: 426-32.
14. Alexander EK, Reed Larsen P. High dose (131)l therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002, 87: 1073-7.
15. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001, 86: 3488-93.
16. Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. EurJ Endocrinol 1999,141: 117-21.
17. Ceccarelli C, Bencivelli W, Vitti P. Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf) 2005, 62: 331-5.
18. Dottorini ME, Inglese E, Salvatori M, Signori A, Squatrito S, Vitti P. II trattamento radiometabolico dell'ipertiroidismo. 2005 http://www. societaitalianadiendocrinologia.it/file/lg-tratt-rad-ipertiro.pdf
19. Snyder W, Ford M, Warner G, Watson S. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11, Society of Nuclear Medicine, New York, NY 1975.
20. Brunn J, Block U, Ruf J, Boa I, Kunze WP, Scriba PC. Volurnetrie der schilddrusenlappen mittels real-time-sonographie. Dtsch Med J 1983, 287: 1206-7.
21. Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab 2003, 88: 975-7.
22. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standar vs. calculated 131-iodine activity. Results from a prospective, randomized, multicentre study. EurJ Clin Invest 1995, 25: 186-93.
23. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Inter Med 2003, 139: 346-51.
24. Farrar JJ, Toft AD. Iodine-i 31 treatment of hyperthyroidism: Current issues. Clin Endocrinol (Oxf) 1991, 35: 207-12.
25. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radiolodine treatment of hyperthyroidism-Prognostic factors for outcome. J Clin Endocrinol Metab 2001, 86: 3611-7.
26. Erem C, Kandemir N, Hacihasanoglu A, Ersö HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: Prognostic factors affecting outcome. Endocrine 2004, 25: 55-60.
27. Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998, 83: 40-6.
28. Marcocci C, Gianchecchi D, Masini I, etal. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 1990,13:513-20.
29. Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves'disease. .J Clin Endocrinol Metab 2007, 92: 3547-52.
30. Sabri 0, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication. J Clin Endocrinol Metab 1999, 84: 1229-33.
31. Walter MA, Briel M, Christ-Cram M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007, 334: 514-7.
32. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidisrn. J Clin Endocrinol Metab 1998, 83: 685-7.
33. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 1038-42.
34. Tarantini B, Ciuoli C, Di Cairano G, et al. Effectiveness of radioiodine (131l) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest 2006, 29: 594-8.